Table 1 Patient demographics and disease characteristics
|  | Patient population N = 715 |
|---|---|
Age, mean years (SD) | 42.1 (10.7) |
Male gender, N (%) | 219 (30.6) |
Ethnicity, N (%) | Â |
 White/Caucasian | 552 (77.2) |
 Afro-Caribbean | 98 (13.7) |
 Spanish/Hispanic | 36 (5.0) |
 Other | 25 (3.5) |
 Missing | 4 (0.6) |
Employment status, N (%) | Â |
 Employed | 422 (59.0) |
Housing status, N (%) | Â |
 Lives alone | 139 (19.4) |
 Lives with partner/spouse | 463 (64.8) |
 Lives with other friends/family | 108 (15.1) |
 Missing | 5 (0.7) |
Relationship status, N (%) | Â |
 Single | 112 (15.7) |
 In a relationship | 476 (66.6) |
 Divorced/separated/widowed | 111 (15.5) |
 Missing | 16 (2.2) |
Time since initial MS diagnosis, mean years(SD) | 6.9 (5.3)a |
Current DMDs, N (%) | Â |
 Interferon beta-1a | 230 (32.2) |
 Interferon beta-1b | 66 (9.2) |
 Glatiramer acetate | 178 (24.9) |
 Dimethyl fumarate | 93 (13.1) |
 Teriflunomide | 22 (3.1) |
 Natalizumab | 56 (7.8) |